Glomerulonephritis – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Tue, 23 Jun 2026 04:06:39 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Glomerulonephritis – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Desmopressin for Prevention of Bleeding After Kidney Biopsy in Patients with Rare Glomerulonephritis https://clinicaltrials.eu/trial/study-on-desmopressin-for-bleeding-prevention-in-patients-with-rare-glomerulonephritis-undergoing-kidney-biopsy/ Wed, 29 Apr 2026 15:02:20 +0000 https://clinicaltrials.eu/trial/study-on-desmopressin-for-bleeding-prevention-in-patients-with-rare-glomerulonephritis-undergoing-kidney-biopsy/ This clinical trial focuses on patients with rare glomerulonephritis, a kidney condition that requires a kidney biopsy for diagnosis. The study aims to evaluate whether a medication called desmopressin can help prevent bleeding complications after kidney biopsy procedures. The medication will be compared to a placebo to determine its effectiveness in reducing bleeding risks.

During the study, participants will receive either Minirin (which contains desmopressin) as an intravenous injection or a placebo before their kidney biopsy procedure. The medication is given as a single dose before the biopsy. Doctors will monitor patients for 24 and 48 hours after the procedure to check for any bleeding complications and changes in blood sodium levels.

The study will look at different types of bleeding events that might occur after the biopsy, including visible blood in urine and bruising around the kidney area. Doctors will also monitor other effects such as changes in heart rate and blood pressure. The overall hospital stay duration and cost-effectiveness of using this medication will be evaluated as part of the study.

]]> Study on the Safety and Effects of OMS906 for Patients with C3 Glomerulopathy and Idiopathic Immune Complex-Mediated Glomerulonephritis https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-oms906-for-patients-with-c3-glomerulopathy-and-idiopathic-immune-complex-mediated-glomerulonephritis/ Wed, 29 Apr 2026 15:01:03 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-oms906-for-patients-with-c3-glomerulopathy-and-idiopathic-immune-complex-mediated-glomerulonephritis/ This clinical trial is focused on studying two kidney diseases: C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN). These conditions affect the kidneys’ ability to filter waste from the blood. The study will use a new investigational drug called OMS906, which is given as a solution for injection. The purpose of the study is to test the safety and effects of OMS906 in people with these diseases.

Participants in the study will receive OMS906 through an intravenous infusion, which means the drug is delivered directly into the bloodstream through a vein. The treatment will be given at regular intervals over a period of time. The study will monitor how well participants tolerate the drug and any side effects they may experience. Additionally, the study will observe changes in kidney function and protein levels in the urine, which are important indicators of kidney health.

The study aims to provide valuable information about the potential benefits and risks of using OMS906 for treating C3G and ICGN. By participating, individuals will contribute to research that could lead to new treatment options for these kidney diseases. The study will continue for a set duration, with regular assessments to track participants’ health and response to the treatment.

]]> Study on the Effects of Belimumab and Rituximab for Patients with Severe Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-the-effects-of-belimumab-and-rituximab-for-patients-with-severe-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 15:00:06 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-belimumab-and-rituximab-for-patients-with-severe-systemic-lupus-erythematosus/ This clinical trial is focused on studying a disease called Systemic Lupus Erythematosus (SLE), which is a condition where the immune system mistakenly attacks healthy tissues in the body. The study is testing a combination of two treatments: Benlysta (belimumab) and Truxima (rituximab). These medications are designed to help manage the symptoms of SLE by targeting specific parts of the immune system. Benlysta is given as an injection under the skin, while Truxima is administered through an infusion into a vein.

The purpose of the study is to see if the combination of Benlysta and Truxima is more effective than the usual treatments, which include medications like mycophenolate and steroids. Participants in the study will receive either the combination treatment or the standard treatment. The study will last for about two years, during which time the effectiveness of the treatments will be monitored. This includes looking at how well the treatments reduce the activity of the disease and how they affect the immune system over time.

Throughout the study, researchers will also keep track of any side effects or safety concerns related to the treatments. The goal is to find out if the combination of Benlysta and Truxima can provide a better long-term outcome for people with severe SLE compared to the standard treatments. This research could lead to improved treatment options for those living with this challenging condition.

]]>